The angioedema treatment market involves products used to treat angioedema that includes drugs and medications. Angioedema results in episodes of acute non-pitting swelling of the dermis, subcutaneous tissues, gastrointestinal tract, and upper respiratory tract. Common symptoms include swelling of the face, lips, tongue, larynx, or extremities. Rising incidences of hereditary angioedema and increasing investments in R&D of novel therapies present opportunity for market growth.

The Global angioedema treatment market is estimated to be valued at US$ 470.4 Mn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2023 to 2030.

Key Takeaways
Key players operating in the angioedema treatment are Bayer AG, Zoetis Inc., Boehringer Ingelheim GmbH, Merck & Co., Inc., Virbac S.A., Ceva Santé Animale, Elanco Animal Health, Bimeda, Aurobindo Pharma Limited, and Teva Pharmaceutical Industries Ltd. These players are investing in developing alternative therapies such as subcutaneous C1-INH therapy to treat hereditary angioedema.
The key opportunities in the angioedema treatment market include rising healthcare investments and increasing awareness about available treatment options. Also, the recent approvals of drugs for prevention and treatment of angioedema attacks present lucrative growth opportunities.
Advancements in recombinant technology have enabled development of novel drug candidates for prophylaxis and on-demand treatment of angioedema. Companies are exploring therapies based on plasma-derived C1-INH concentrate as well as recombinant human C1-INH to expand treatment options.

Market Drivers
The increasing prevalence of angioedema globally is a major market driver. As per estimates, about 1 in 10,000 to 1 in 150,000 people are affected by hereditary angioedema worldwide. Favorable government policies and grants to support R&D for orphan drugs will also support the market growth during the forecast period.

Challenges in Angioedema Treatment Market
The angioedema treatment market faces various challenges. Higher treatment cost impacts adoption rates as angioedema treatment therapies involve high cost. Recurrence of attacks is also a challenge as it requires repeated treatment and impacts quality of life. Poor healthcare infrastructure and lack of awareness in developing nations restrict market growth.

SWOT Analysis
Strength: Wide range of treatment options available including C1 esterase inhibitors, bradykinin receptor antagonists and plasma kallikrein inhibitors. Growing research and development activities by major players.
Weakness: High treatment cost and risk of side effects associated with approved drugs. Difficulty in self-administration of drugs.
Opportunity: Increasing incidence rates of hereditary angioedema drives the demand. Growing healthcare expenditure in developing nations creates scope.
Threats: Patent expiry of existing drugs allows for the entry of generic versions. Strong regulatory framework delays drug approval.

Geographical Regions
North America holds the largest market share currently in terms of value due to high healthcare expenditure and availability of advanced treatments. Growing awareness among patients and presence of major players in the region drive the market.

The Asia Pacific region is expected to grow at the fastest rate during the forecast period driven by economies like India and China. Factors such as rising healthcare investments, large patient population and increasing government initiatives to modernize healthcare systems support market growth in the region.